E. Esın Et Al. , "Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes.," Cancer chemotherapy and pharmacology , vol.83, pp.131-143, 2019
Esın, E. Et Al. 2019. Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes.. Cancer chemotherapy and pharmacology , vol.83 , 131-143.
Esın, E., Oksuzoglu, B., Bılıcı, A., Cıcın, I., Köstek, O., Kaplan, M., ... Aksoy, S.(2019). Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes.. Cancer chemotherapy and pharmacology , vol.83, 131-143.
Esın, E Et Al. "Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes.," Cancer chemotherapy and pharmacology , vol.83, 131-143, 2019
Esın, E Et Al. "Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes.." Cancer chemotherapy and pharmacology , vol.83, pp.131-143, 2019
Esın, E. Et Al. (2019) . "Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes.." Cancer chemotherapy and pharmacology , vol.83, pp.131-143.
@article{article, author={E Esın Et Al. }, title={Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes.}, journal={Cancer chemotherapy and pharmacology}, year=2019, pages={131-143} }